Day: January 2, 2025

« Sword is embarking on the implementation of its 2028 Business Plan with great confidence, backed by the excellence of its employees, the loyalty of its customers and the solidity of its investors.We are approaching this new period with a clear strategic vision, anticipating market developments to transform every challenge, risk or constraint into a real opportunity for growth. » Jacques MottardChairman & CEO OUR STRATEGIC PRINCIPLES A High-Performance, Committed Management Organisation At Sword, we embody a management style based on action and involvement. Every manager, at every level, plays a dual role of, “doing ” and “getting things done “, to boost efficiency and cohesion. Long-term and Multidimensional Growth Our balanced and ambitious growth strategy is built around three key areas for the next four...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”). ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. This acceptance also triggers a milestone payment from AstraZeneca. The...